New COVID-19 vaccine candidate enters early human testing
NCT ID NCT05408312
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new recombinant COVID-19 vaccine (GEN2) in 234 healthy adults aged 18 and older. The main goal was to check safety and how well the body's immune system responds. Participants received one of three different doses or a placebo, and researchers monitored for side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant SARS-CoV-2 Vaccine (CHO cells, NVSI-06-08)
- What this could lead to
- If successful, this could lead to a new COVID-19 vaccine option that is safe and triggers an immune response.
- What could go wrong
- This is an early Phase 1 trial with only 234 participants, so safety and effectiveness are not yet proven. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple inhaled combo keep pneumonia patients off ventilators?
- Simple breathing and walking exercises may speed lung recovery after COVID-19 pneumonia
- Can a smartphone app heal the hidden wounds of the ICU?
- Ultrasound peek at lungs after COVID: small study, big questions
- Could stem cells help COVID-19 patients breathe easier?
- Vaccinated still got COVID: new study counts breakthrough cases